High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform
使用支持 iPSC 的平台对化合物滥用倾向进行高通量分析并识别与成瘾相关的药物靶标
基本信息
- 批准号:9912598
- 负责人:
- 金额:$ 32.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-30 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnalgesicsAstrocytesBenchmarkingBiological AssayBiological MarkersBiological SciencesCell LineCell LineageCellsClassificationData AnalysesDevelopmentDrug TargetingEconomic BurdenElectrophysiology (science)Emergency SituationEngineeringGene ExpressionGene Expression AlterationGene Expression ProfilingGene ProteinsGenerationsGlutamatesGovernmentGrowthHumanIn VitroMachine LearningMeasurementMeasuresMethodsMicroscopyModelingMolecularMolecular ProfilingNervous system structureNeuronsOpiate AddictionPharmaceutical PreparationsPhasePhenotypePhysiologicalPhysiologyPositioning AttributeProcessPropertyProtein ArrayProteomicsPublic HealthReporterSpecificityStructureTechnologyTestingTherapeuticTransfectionUnited States National Institutes of HealthValidationaddictionbasedesigndopaminergic neurondrug discoveryexpression vectorhealingin vitro Assayin vitro Modelinduced pluripotent stem cellinnovationmortalitymulti-electrode arraysnew therapeutic targetnovel strategiesnovel therapeuticsopioid epidemicpreventprogramspromoterprotein expressionstemtargeted biomarkertherapeutic candidatetooltranscriptometranscriptome sequencingvector
项目摘要
Project Summary/Abstract
The scale of the US opioid addiction crisis clearly evidences the critical need for breakthroughs to assess
compound abuse liabilities and to enable discovery of new analgesics with minimal abuse potential. We
hypothesize that altered addiction-associated physiology can be modeled in co-cultured hiPSC-derived neuronal
and astrocyte cells and detected by profiling gene expression alterations and associated phenotypic readouts.
Our proposal addresses the significant lack of physiologically-relevant tools capable of profiling relevant
molecular changes that underpin addiction in the human nervous system by executing Specific Aims that
encompass: (1) generation of a panel of multicolor hiPSC-derived neuronal and astrocyte cells with stable
lineage specific fluorescent reporters; (2) execution of a phenotype-based pilot machine learning-enabled
predictive abuse liability screen; and (3) combination of phenotypic profiling and gene expression analysis to
characterize the molecular and cellular changes associated with compound exposure. Successful completion of
our project will deliver 2 significant advances: (1) an important new technical framework to assess abuse potential
of candidate therapeutics early in the development process and (2) an innovative, scalable in vitro assay platform
that enables discovery of targets and associated candidate therapeutics to mitigate addiction phenotypes. These
innovations will position Cairn Biosciences to initiate drug discovery programs that will bring significant societal
benefit by helping to stem the growth of the US opioid crisis and reduce the mortality rates and economic burden
associated with this National Emergency.
项目总结/摘要
美国阿片类药物成瘾危机的规模清楚地证明了迫切需要突破,以评估
复合滥用倾向,并能够发现新的镇痛剂与最小的滥用潜力。我们
假设改变成瘾相关生理学可以在共培养的hiPSC衍生的神经元中建模
和星形胶质细胞,并通过分析基因表达改变和相关的表型读数来检测。
我们的建议解决了严重缺乏生理相关的工具,能够分析相关的
通过执行特定目标来支持人类神经系统成瘾的分子变化,
包括:(1)产生一组具有稳定的细胞增殖的HiPSC衍生的神经元和星形胶质细胞。
谱系特异性荧光报告基因;(2)执行基于表型的试点机器学习
预测性滥用倾向筛查;以及(3)表型分析和基因表达分析的组合,
表征与化合物暴露相关的分子和细胞变化。成功完成
我们的项目将带来两个重大进展:(1)一个重要的新技术框架,以评估滥用的可能性
开发过程早期的候选疗法和(2)创新的、可扩展的体外检测平台
这使得能够发现靶点和相关的候选治疗剂以减轻成瘾表型。这些
创新将使凯恩生物科学公司能够启动药物发现计划,
通过帮助遏制美国阿片类药物危机的增长并降低死亡率和经济负担而受益
与此次国家紧急状态有关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Celine Maeder其他文献
Celine Maeder的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 32.38万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 32.38万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 32.38万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 32.38万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 32.38万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 32.38万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 32.38万 - 项目类别:
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 32.38万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 32.38万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 32.38万 - 项目类别: